Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus

Why It Matters

The GLP‑1 partnership could unlock a higher‑margin revenue stream for Hims & Hers, reshaping its growth trajectory in a competitive telehealth market. Investors will gauge whether the deal translates into sustainable top‑line momentum and improves the stock’s risk‑adjusted profile.

Key Takeaways

• Hims & Hers now sells Novo Nordisk’s Wegovy and Ozempic
• Deal may not boost Q1 revenue; impact expected in Q2
• Subscriber base holds above 2.5 million with 82% three‑month retention
• EPS forecast 3‑4 cents, implying ~90% YoY decline
• Short interest exceeds 35% of float, driving high volatility

Pulse Analysis

The alliance with Novo Nordisk marks a pivotal shift for Hims & Hers, moving the company from compounded GLP‑1 formulations to FDA‑approved, brand‑name therapies. By leveraging its direct‑to‑consumer model, Hims can tap into the booming obesity‑treatment market, where Wegovy and Ozempic command premium pricing and strong demand. This move also mitigates regulatory risk after the FDA signaled tighter controls on 503B bulk drugs, positioning the firm to capture higher margins while expanding its pharmaceutical portfolio.

Subscriber growth remains a cornerstone of Hims & Hers’ valuation. Crossing the 2.5 million threshold demonstrates that the platform’s integrated care model resonates with consumers seeking convenient, recurring health solutions. With roughly 82% of users staying beyond three months, the company generates about 90% of its recurring revenue from a loyal base, a metric that investors scrutinize for stability. In a broader telehealth context, the firm’s ability to sustain this engagement could differentiate it from rivals that rely more heavily on episodic visits.

Valuation and market sentiment are mixed. Analysts forecast Q1 revenue of $616‑$619 million but warn that earnings per share may plunge to 3‑4 cents, reflecting a near‑90% year‑over‑year decline. The stock’s high beta of 2.43 and short interest above 35% underscore its volatility, while institutional ownership near 64% suggests a degree of confidence. A stronger‑than‑expected earnings beat could accelerate the stock toward the consensus $31.86 target, but any miss may deepen the sell‑off, especially given the sector’s broader weakness in 2026.